Tratamento do transtorno bipolar durante a gravidez
DOI:
https://doi.org/10.25118/2763-9037.2018.v8.330Palavras-chave:
Transtorno bipolar, gravidez, estabilizadores do humorResumo
Esta revisão tem por objetivo discutir criticamente as diversas diretrizes existentes para o tratamento do transtorno bipolar durante a gravidez. Abordam-se os riscos de recaídas (maníacas e depressivas) no curso da gravidez, em contraposição aos riscos e benefícios vinculados ao uso dos diversos medicamentos para o tratamento do transtorno bipolar. As diferentes diretrizes são abordadas em suas divergências e convergências. São discutidos os benefícios e riscos potenciais dos estabilizadores do humor (sais de lítio e anticonvulsivantes), assim como os dados existentes sobre os antipsicóticos típicos e atípicos.
Downloads
Métricas
Referências
Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2,252 pregnancies and ostpartum periods. Am. J. Psychiatry. 2011;168:1179-85.
Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systemati c review and meta-analysis. Am J Psychiatry. 2016;173:117-27.
Graham RK, Tavella G, Parker GB. Is there consensus across internati onal evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Aff ect Disord. 2018;228:216-21.
Galbally M, Snellen M, Lewis A. Psychopharmacology and pregnancy – treatment effi cacy, risks, and guidelines. Heidelberg: Springer; 2014.
Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproducti ve events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63:284-7.
Blehar MC, DePaulo JR Jr, Gershon ES, Reich T, Simpson SG, Nurnberger JI Jr. Women with bipolar disorder: fi ndings from the NIMH
Geneti cs Initi ati ve sample. Psychopharmacol Bull. 1998;34:239-43.
Viguera AC, Whitfi eld T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospecti ve study of mood stabilizer disconti nuati on. Am J Psychiatry. 2007;164:1817-24; quiz 1923.
Boden R, Lundgren M, Brandt L, Reutf ors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: populati on based cohort study. BMJ. 2012;345:e7085.
Joff e H. Reproducti ve biology and psychotropic treatments in premenopausal women with bipolar disorder. J Clin Psychiatry. 2007;68:10-5.
Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand college of psychiatrists clinical practi ce guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087-206.
American Psychiatric Associati on (APA). Guideline watch for the practi ce guideline for the treatment of pati ents with bipolar disorder. Arlington: APA; 2005.
Management of Bipolar Disorder Working Group. VA/DoD clinical practi ce guideline for management of bipolar disorder in adults [Internet]. 2010 [cited 2019 May 02]. www.healthquality.va.gov/bipolar/bd_306_sum.pdf
World Health Organizati on (WHO). Pharmacological treatment of mental disorders in primary health care. Geneva: WHO; 2009.
Goodwin GM; Consensus Group of the Briti sh Associati on for Psychopharmacology. Evidencebased guidelines for treati ng bipolar disorder, revised second editi on: recommendati ons from the Briti sh Associati on for Psychopharmacology. J Psychopharmacol. 2009;23:346-88.
Nati onal Insti tute for Health and Care Excellence (NICE). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care [Internet]. Clinical guideline [CG38]. 2006 Jul [cited 2019 May 02]. www.nice.org.uk/guidance/cg38
Yatham LN, Kennedy SH, Parikh SV, Schaff er A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and Internati onal Society for Bipolar Disorders (ISBD) collaborati ve update of CANMAT guidelines for the management of pati ents with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.
Yatham LN, Kennedy SH, Parikh SV, Schaff er A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20: 97-170.
Kanba S, Kato T, Terao T, Yamada K; Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders. Psychiatry Clin. Neurosci. 2013;67:285-300.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10:85-116.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. Task Force on Treatment Guidelines for Bipolar Disorders,
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81-109.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the longterm treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154-219.
Iqbal MM, Gundlapalli SP, Ryan WG, Ryals T, Passman TE. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J. 2001;94:304-22.
Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608-20.
Patel N, Viguera AC, Baldessarini RJ. Moodstabilizing anticonvulsants, spina bifida, and folate supplementation: commentary. J Clin Psychopharmacol. 2018;38:7-10.
Raghavan R, Riley AW, Volk H, Caruso D, Hironaka L, Sices L, et al. Maternal multivitamin intake, plasma folate and vitamin B12 levels and autism spectrum disorder risk in offspring. Paediatr Perinat Epidemiol. 2018;32:100-11.
Paton C, Cookson J, Ferrier IN, Bhatti S, Fagan E, Barnes TR. A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. BMJ Open. 2018;8:e020450.
Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry. 1975;132:529-31.
Osiro S, Tiwari KJ, Mathenge N, Rodriguez JR, Tubbs RS, Loukas M. When lithium hurts: a look at Ebstein anomaly. Cardiol Rev. 2013;21:257-63.
Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the register of lithium babies. Br Med J. 1973;2:135-6.
Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146-50.
Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11:425-37.
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721-8.
Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162:2162-70.
Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry. 1998;59 Suppl 6:57-64.
van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88:375-8.
Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. Hoboken: Wiley-Blackwell; 2015.
Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG. 2009;116:758-67.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformati on risks of anti epilepti c drugs in pregnancy: a prospecti ve study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-8.
Jones KL, Lacro RV, Johnson KA, Adams J. Patt ern of malformati ons in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989;320:1661-6.
Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? A prospecti ve controlled study of 210 pregnancies. Neurology. 2001;57:321-4.
Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrati ons of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia. 2008;49: 1075-80.
Hunt SJ, Craig JJ, Morrow JI. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2009;72:1108.
Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;27;70:2152-8.
Diav-Citrin O, Shechtman S, Zvi N, FinkelPekarsky V, Ornoy A. Is it safe to use lamotrigine during pregnancy? A prospecti ve comparati ve observati onal study. Birth Defects Res. 2017;109:1196-203.
Meador KJ, Pennell PB, Harden CL, Gordon JC, Tomson T, Kaplan PW, et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology. 2008;71:1109-17.
Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, García-Fiñana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to anti epilepti c drugs. J Neurol Neurosurg Psychiatry. 2013;84:637-43.
Einarson A, Boskovic R. Use and safety of anti psychoti c drugs during pregnancy. J Psychiatr Pract. 2009;15:183-92.
Genti le S. Anti psychoti c therapy during early and late pregnancy. A systemati c review. Schizophr Bull. 2010;36:518-44.
Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Anti psychoti c use in pregnancy and the risk for congenital malformati ons. JAMA Psychiatry. 2016;73:938-46.
Newham JJ, Thomas SH, MacRitchie K, McElhatt on PR, McAllister-Williams RH. Birth weight of infants aft er maternal exposure to typical and atypical anti psychoti cs: prospecti ve comparison study. Br J Psychiatry. 2008;192:333-7.
Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal psychotropic medicati on and neonatal behavior. Neurotoxicol Teratol. 1992;14:399-406.
Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, et al. Eff ects of prenatal exposure to atypical anti psychoti cs on postnatal development and growth of infants: a case-controlled, prospecti ve study. Psychopharmacology (Berl). 2013;228:577-84.
Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal anti psychoti c exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69:787-94.
Galbally M, Snellen M, Power J. Anti psychoti c drugs in pregnancy: a review of their maternal and fetal eff ects. Ther Adv Drug Saf. 2014;5:100-9.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
